For patients with AML, MM, and CML there was an increase in hazard of death for those on SGLT2 inhibitors after adjusting for the additional covariates (AML HR 2.47, CI 1.45–4.16, p < 0.001; MM HR 2.44, CI 1.51–3.95, p < 0.001; CML HR 3.46, CI 1.15–10.4, p = 0.027) (Supplementary Table S13). This evidence concerns the gene SLC5A2 and acute myeloid leukemia.